Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 02	STN pricing information for 2008 now available
NEWS 3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5	JAN 28	MARPAT searching enhanced
NEWS 6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9	FEB 08	STN Express, Version 8.3, now available
NEWS 10	FEB 20	PCI now available as a replacement to DPCI
NEWS 11	FEB 25	IFIREF reloaded with enhancements
NEWS 12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 29	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 30	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 31	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated

```
                  organizations
 NEWS 32  JUN 30  STN on the Web enhanced with new STN AnaVist
                  Assistant and BLAST plug-in
 NEWS 33  JUN 30  STN AnaVist enhanced with database content from EPFULL

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:09:40 ON 16 JUL 2008

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 09:10:00 ON 16 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   15 JUL 2008  HIGHEST RN 1034171-01-1
DICTIONARY FILE UPDATES:  15 JUL 2008  HIGHEST RN 1034171-01-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10530571.str
```



chain nodes :
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
ring nodes :
1 2 3 4 5 6 7 8 9 10 11
chain bonds :
8-14 8-15 9-12 9-13 10-16 11-17 17-18 17-26 18-19 18-25 19-20 19-27
20-21 20-24 21-22 21-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-11 7-8 8-9 9-10 10-11
exact bonds :
5-7 6-11 7-8 8-9 8-14 8-15 9-10 9-12 9-13 10-11 10-16 11-17 17-18
17-26 18-19 18-25 19-20 19-27 20-21 20-24
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 21-22 21-23
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS
27:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS

```
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 full
FULL SEARCH INITIATED 09:10:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       65 TO ITERATE

100.0% PROCESSED       65 ITERATIONS                              26 ANSWERS
SEARCH TIME: 00.00.01

L2           26 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     178.36     178.57

FILE 'CAPLUS' ENTERED AT 09:10:25 ON 16 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 16 Jul 2008  VOL 149 ISS 3
FILE LAST UPDATED: 15 Jul 2008  (20080715/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l2 full
L3           9 L2

=> d ibib abs hitstr tot
```

L3 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:639779 CAPLUS
DOCUMENT NUMBER: 149:1495
TITLE: Methods of treating neuropathic pain with agonists of PPAR-γ
INVENTOR(S): Chiang, Lillian W.; Honore, Tage
PATENT ASSIGNEE(S): Aestus Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 80pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008063842	A2	20080529	WO 2007-US83326	20071101

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-864095P P 20061102
OTHER SOURCE(S): MARPAT 149:1495

AB Embodiments of the invention relate to the treatment of neuropathic pain in mammals. Embodiments of the invention include methods for treating neuropathic pain as well as methods for preparing medicaments used in the treatment of mammalian pain. Preferably, methods of the invention comprise the use of PPAR-γ agonists for the treatment of mammalian pain.

IT 280585-34-4, Oxeglitazar 280585-34-4D, Oxeglitazar, esters
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treating neuropathic pain with agonists of PPAR-γ)

RN 280585-34-4 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-34-4 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



L3 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1069214 CAPLUS
DOCUMENT NUMBER: 147:433271
TITLE: Supercritical Antisolvent Versus Coevaporation - Preparation and Characterization of Solid Dispersions
AUTHOR(S): Majerik, Viktor; Horvath, Geza; Szokonya, Laszlo; Charbit, Gerard; Badens, Elisabeth; Bosc, Nathalie; Teillaud, Eric
CORPORATE SOURCE: Department of Chemical Engineering Science, University of Pannonia, Veszprem, Hung.
SOURCE: Drug Development and Industrial Pharmacy (2007), 33(9), 975-983
CODEN: DDIPD8; ISSN: 0363-9045
PUBLISHER: Informa Healthcare
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The objective of this work was to improve the dissoln. rate and aqueous solubility of oxeglitazar. Solid dispersions of oxeglitazar in PVP K17 (polyvinilpyrrolidone) and poloxamer 407 (polyoxyethylene-polyoxypropylene block copolymer) were prepared by supercrit. antisolvent (SAS) and coevaporation (CoE) methods. Drug-carrier formulations were characterized by powder x-ray diffraction, Fourier transform IR spectroscopy, SEM, gas chromatog., UV/VIS spectroscopy and in vitro dissoln. tests. The highest dissoln. rate (nearly 3-fold higher than raw drug) was achieved by preparation of drug/PVP K17 coevaporate. Oxeglitazar/PVP K17 solid dispersions were stabilized by hydrogen bonding but contained higher amount of residual dichloromethane (DCM) than poloxamer 407 formulations regardless of the method of preparation SAS prepared oxeglitazar/poloxamer 407 dissolved more than two times faster than raw drug. However, unlike PVP K17, poloxamer 407 did not form a single phase amorphous solid solution with oxeglitazar which has been manifested in higher degrees of crystallinity, too. Among the two techniques, evaluated in this work, conventional coevaporation resulted in higher amorphous content but SAS reduced residual solvent content more efficiently.

IT 280585-34-4, Oxeglitazar
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(comparison of supercrit. antisolvent and coevaporation method for preparation and characterization of solid dispersions)

RN 280585-34-4 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1328491 CAPLUS
DOCUMENT NUMBER: 146:190124
TITLE: Bioavailability enhancement of an active substance by supercritical antisolvent precipitation
AUTHOR(S): Majerik, Viktor; Charbit, Gerard; Badens, Elisabeth; Horvath, Geza; Szokonya, Laszlo; Bosc, Nathalie; Teillaud, Eric
CORPORATE SOURCE: Department of Chemical Engineering, Pannon University, Veszprem, H-8201, Hung.
SOURCE: Journal of Supercritical Fluids (2007), 40(1), 101-110
CODEN: JSFLEH; ISSN: 0896-8446
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Oxeglitazar is a new orally administered poorly water soluble active substance used in the treatment of type II diabetes. Our research aimed to improve the bioavailability of this active substance using Supercrit. Antisolvent (SAS) process. Oxeglitazar was copptd. with various solubilizing excipients: polyoxyethylene-polyoxypropylene block copolymers (Poloxamer 188 and 407), polyethylene glycol (PEG 8000) and polyvinilpyrrolidone (PVP K17) from six different solvents: Ethanol (EtOH), THF, dichloromethane (DCM), chloroform ($CHCl_3$), N-methyl-2-pyrrolidone (NMP), dimethylsulfoxide (DMSO) and two binary solvent mixts.: EtOH/THF (50:50%, volume/volume) and EtOH/$CHCl_3$ (50:50%, volume/volume). Formulations were compared in terms of particle morphol., crystallinity, polymorphic purity, residual solvent content, precipitation yield and dissoln. kinetics. SAS formulations of oxeglitazar-PEG 8000, Poloxamer 188 and 407 contained acicular drug crystals that were partly embedded in polymeric spheres while expts. with PVP K17 resulted in quasi amorphous solid dispersions with high d. and good flowability. In spite of the greater particle size, SAS formulations exhibited significantly greater dissoln. rate compared to raw drug and phys. mixts. More than twice as much active substance was dissolved at 5 min from Poloxamer 407 and PVP K17 formulations than from unprocessed drug. In addition, SAS prepared Poloxamer 407 formulation from DCM solution exhibited high polymorphic purity, good flow properties, acceptable precipitation yield and low residual solvent content.
IT 280585-34-4, Oxeglitazar
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bioavailability enhancement of an active substance by supercrit. antisolvent precipitation)
RN 280585-34-4 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1253003 CAPLUS
DOCUMENT NUMBER: 146:804
TITLE: insulin sensitization for delaying puberty and increasing growth
INVENTOR(S): De Zegher, Francis; Dunger, David; Ibanez, Lourdes
PATENT ASSIGNEE(S): K.U. Leuven Research and Development, Belg.; Addenbrooke's Hospital
SOURCE: PCT Int. Appl., 61pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006125285	A1	20061130	WO 2006-BE60	20060523
WO 2006125285	B1	20070111		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: GB 2005-10469 A 20050523
OTHER SOURCE(S): MARPAT 146:804

AB In accordance with the purpose of the invention, as embodied and broadly described herein, the invention is broadly drawn to a new method of treatment, the use of agents to manufacture a composition of treatment or the composition of treatment for the prevention of rapidly progressive puberty, the prevention of early menarche or the modulation, more particularly the delay, of the tempo of puberty in a female mammal, preferably a human girl, and the disorders related thereto. In a particular embodiment the present invention involves the use of at least one insulin-sensitizing agent such as metformin, any of the polymorphs of metformin or a pharmaceutically acceptable salt thereof for the preparation of a composition of treatment to modulate the tempo of pubertal progression in a girl. Metformin administration to girls experiencing precocious puberty resulted in normalization of pubertal progression to menarche, increased height gains, leaner body composition, and decreases indexes relating to insulin resistance.

IT 280585-34-4, Oxeglitazar
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(metformin-induced insulin sensitization for delaying puberty and increasing growth)

RN 280585-34-4 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1345487 CAPLUS
DOCUMENT NUMBER: 144:69749
TITLE: Preparation of 3,3-dimethylbenzoxepin-5-ylalkenones as intermediates for antidiabetic pentadienoic acids
INVENTOR(S): Brunet, Michel; Le Borgne, Guy
PATENT ASSIGNEE(S): Merck Sante, Fr.
SOURCE: Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1609786	A1	20051228	EP 2004-291616	20040625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
WO 2006002721	A1	20060112	WO 2005-EP5693	20050527
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1758876	A1	20070307	EP 2005-747039	20050527
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LV				

PRIORITY APPLN. INFO.: EP 2004-291616 A 20040625
WO 2005-EP5693 W 20050527
OTHER SOURCE(S): CASREACT 144:69749; MARPAT 144:69749
GI



I

AB Title compds. [I; R = H, (substituted) alkyl, aryl; R1 = halo, cyano, NO2, CO2H, (halo)alkoxycarbonyl, etc.; p = 0-4], were prepared Thus, 3,3-dimethyl-7-ethyl-2,3,4,5-tetrahydrobenzoxazepin-5-one, triflic anhydride, and pyridine were refluxed together in CH2Cl2 for 4 h to give 100% 3,3-dimethyl-5-trifluoromethanesulfonyloxy-7-ethyl-2,3-dihydroobenzoxazepine. The latter was heated with Me vinyl ketone,

(PPh3)2PdCl2, and Et3N in DMF at 70-75° for 5 h to give 96% (3E)-4-(3,3-dimethyl-7-ethyl-2,3-dihydrobenzoxepin-5-yl)buten-2-one.

IT 280585-64-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of dimethylbenzoxepinylalkenones as intermediates for antidiabetic pentadienoic acids)

RN 280585-64-0 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-ethyl-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:523273 CAPLUS
DOCUMENT NUMBER: 143:53517
TITLE: Use of pentadienoic acid derivatives for the treatment of hyperuricemia
INVENTOR(S): Boizel, Robert; Fouqueray, Pascale; Guerrier, Daniel; Zeiller, Jean-Jacques; Brutzkus, Bertrand
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005053676	A1	20050616	WO 2004-EP12381	20041102
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1535612	A1	20050601	EP 2003-292973	20031128
EP 1535612	B1	20060913		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004294686	A1	20050616	AU 2004-294686	20041102
CA 2547543	A1	20050616	CA 2004-2547543	20041102
EP 1686983	A1	20060809	EP 2004-797525	20041102
EP 1686983	B1	20070711		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1886129	A	20061227	CN 2004-80035212	20041102
BR 2004017003	A	20070116	BR 2004-17003	20041102
JP 2007512267	T	20070517	JP 2006-540224	20041102
IN 2006KN00961	A	20070420	IN 2006-KN961	20060418
MX 2006PA05788	A	20060714	MX 2006-PA5788	20060522
US 20070099854	A1	20070503	US 2006-580602	20060525

PRIORITY APPLN. INFO.:		EP 2003-292973	A	20031128
		US 2003-527773P	P	20031209
		WO 2004-EP12381	W	20041102

OTHER SOURCE(S): MARPAT 143:53517
GI



I

AB The use of a pentadienoic acid derivative of formula I (e.g.,

(2E,4E)-5-(3,3-dimethyl-7-methoxy-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta -2,4-dienoic acid) is claimed for the preparation of a medicament for the prevention or treatment of hyperuricemia and/or one or several associated disorders or diseases, and/or for reducing the serum uric acid level of a subject. Medical compns. for these prevention and/or treatment, comprising such a pentadienoic acid derivative

IT 280585-34-4, (2E,4E)-5-(2,3-Dihydro-3,3-Dimethyl-7-methoxy-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-39-9, (2Z,4E)-5-(3,3-Dimethyl-7-methoxy-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-41-3, (2E,4E)-5-(3,3-Dimethyl-7,8-dimethoxy-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-43-5, (2E,4E)-5-(3,3-Dimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-45-7, (2E,4E)-5-[3,3-Dimethyl-2,3-dihydro-7-(para-chlorobenzoyl)-1-benzoxepin-5-yl]-3-methylpenta-2,4-dienoic acid 280585-47-9, (2E,4E)-5-(3,3-Dimethyl-7-chloro-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-48-0, (2E,4E)-5-(3,3-Dimethyl-7,8-dichloro-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-50-4, (2E,4E)-5-(3,3-Dimethyl-7-bromo-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-51-5, (2E,4E)-5-(3,3-Dimethyl-7-fluoro-8-chloro-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-53-7, (2E,4E)-5-(3,3-Dimethyl-7-fluoro-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-55-9, (2E,4E)-5-(3,3-Dimethyl-7-trifluoromethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-57-1, (2E,4E)-5-(3,3-Dimethyl-7-phenyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280586-03-0, (2E,4E)-5-(3,3,7-Trimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 852550-63-1, (2E,4E)-5-(9-Methoxy-3,3-dimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of pentadienoic acid derivs. for treatment of hyperuricemia)

RN 280585-34-4 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-39-9 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2Z,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-41-3 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7,8-dimethoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-43-5 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-45-7 CAPLUS
CN 2,4-Pentadienoic acid, 5-[7-(4-chlorobenzoyl)-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-47-9 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7-chloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-48-0 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7,8-dichloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-50-4 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7-bromo-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-51-5 CAPLUS
CN 2,4-Pentadienoic acid, 5-(8-chloro-7-fluoro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-53-7 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7-fluoro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-55-9 CAPLUS
CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-3,3-dimethyl-7-(trifluoromethyl)-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-57-1 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3-dimethyl-7-phenyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280586-03-0 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3,7-trimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 852550-63-1 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-9-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:467780 CAPLUS
DOCUMENT NUMBER: 143:1300
TITLE: Use of pentadienoic acid derivatives for the prevention and/or the treatment of hyperuricemia
INVENTOR(S): Boizel, Robert; Fouqueray, Pascale; Guerrier, Daniel; Zeller, Jean-Jacques; Brutzkus, Bertrand
PATENT ASSIGNEE(S): Merck Sante, Fr.
SOURCE: Eur. Pat. Appl., 45 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1535612	A1	20050601	EP 2003-292973	20031128
EP 1535612	B1	20060913		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AT 339200	T	20061015	AT 2003-292973	20031128
ES 2272926	T3	20070501	ES 2003-292973	20031128
AU 2004294686	A1	20050616	AU 2004-294686	20041102
CA 2547543	A1	20050616	CA 2004-2547543	20041102
WO 2005053676	A1	20050616	WO 2004-EP12381	20041102
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1686983	A1	20060809	EP 2004-797525	20041102
EP 1686983	B1	20070711		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1886129	A	20061227	CN 2004-80035212	20041102
BR 2004017003	A	20070116	BR 2004-17003	20041102
JP 2007512267	T	20070517	JP 2006-540224	20041102
AT 366570	T	20070815	AT 2004-797525	20041102
ES 2286692	T3	20071201	ES 2004-797525	20041102
IN 2006KN00961	A	20070420	IN 2006-KN961	20060418
MX 2006PA05788	A	20060714	MX 2006-PA5788	20060522
US 20070099854	A1	20070503	US 2006-580602	20060525

PRIORITY APPLN. INFO.:	EP 2003-292973	A	20031128
	US 2003-527773P	P	20031209
	WO 2004-EP12381	W	20041102

OTHER SOURCE(S): MARPAT 143:1300

AB Use of pentadienoic acid derivs. for the prevention and/or the treatment of hyperuricemia and/or associated disorders or diseases. The use of a pentadienoic acid derivative of formula (I) for the preparation of a medicament for the prevention or treatment of hyperuricemia and/or one or several associated disorders or diseases, and/or for reducing the serum uric acid level of a subject. Medical compns. for these prevention and/or treatment, comprising such a pentadienoic acid derivative

IT 280585-34-4 280585-39-9 280585-41-3

280585-43-5 280585-45-7 280585-47-9
280585-48-0 280585-50-4 280585-51-5
280585-53-7 280585-55-9 280585-57-1
280586-03-0 852550-63-1
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of pentadienoic acid derivs. for prevention and the treatment of hyperuricemia)

RN 280585-34-4 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-39-9 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2Z,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-41-3 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7,8-dimethoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-43-5 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-45-7 CAPLUS
CN 2,4-Pentadienoic acid, 5-[7-(4-chlorobenzoyl)-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-47-9 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7-chloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-48-0 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7,8-dichloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-50-4 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7-bromo-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-51-5 CAPLUS
CN 2,4-Pentadienoic acid, 5-(8-chloro-7-fluoro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-53-7 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7-fluoro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-55-9 CAPLUS
CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-3,3-dimethyl-7-(trifluoromethyl)-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-57-1 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3-dimethyl-7-phenyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280586-03-0 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3,7-trimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 852550-63-1 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-9-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:291092 CAPLUS
DOCUMENT NUMBER: 140:303553
TITLE: New metastable benzoxepine derivatives used for treating dyslipidemia, atherosclerosis, and diabetes, pharmaceutical compositions containing them, and their preparation processes by salt formation and acidulation
INVENTOR(S): Bosc, Nathalie; Festal, Didier; Boudet, Bernard
PATENT ASSIGNEE(S): Merck Sante, Fr.
SOURCE: Fr. Demande, 29 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2845386	A1	20040409	FR 2002-12432	20021007
FR 2845386	B1	20060630		
CA 2502877	A1	20040415	CA 2003-2502877	20030901
WO 2004031166	A1	20040415	WO 2003-EP9680	20030901
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003264139	A1	20040423	AU 2003-264139	20030901
EP 1549630	A1	20050706	EP 2003-798880	20030901
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006503073	T	20060126	JP 2004-540566	20030901
US 20060041007	A1	20060223	US 2005-530571	20050407

PRIORITY APPLN. INFO.: FR 2002-12432 A 20021007
WO 2003-EP9680 W 20030901

OTHER SOURCE(S): MARPAT 140:303553
GI



I

AB The invention is directed to the preparation of new metastable benzoxepines I by salt formation of I and precipitation of I by acidulation of the aqueous salt

solution, and their use for treating dyslipidemia, atherosclerosis, and diabetes [n = 0, 1, or 2; R = independently alkyl, alkoxy, halo]. Thus, addition of aqueous NaOH solution to the stable form of I (R = OMe) (II), followed by acidulation with aqueous H2SO4 afforded the metastable form of II in 99% yield (m.p. = 151-153° by DTA). The metastable form has a higher sp. surface area than the stable form, while their densities are comparable.

IT 280585-34-4P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(intermediate stable form, metastable product; preparation of metastable benzoxepines by salt formation and acidulation for treating dyslipidemia, atherosclerosis, and diabetes)

RN 280585-34-4 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:457054 CAPLUS
DOCUMENT NUMBER: 133:89445
TITLE: Preparation of benzopyrans and benzoxepines and their hypolipidemic and antidiabetic activity
INVENTOR(S): Brunet, Michel; Zeiller, Jean Jaques; Berthelon, Jean Jaques; Contard, Francis; Augert, Guy; Guerrier, Daniel
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000039113	A1	20000706	WO 1999-EP10114	19991220
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2787789	A1	20000630	FR 1998-16574	19981229
FR 2787789	B1	20020614		
CA 2356680	A1	20000706	CA 1999-2356680	19991220
BR 9916633	A	20010925	BR 1999-16633	19991220
EP 1140893	A1	20011010	EP 1999-967960	19991220
EP 1140893	B1	20030305		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
HU 2001004839	A2	20020429	HU 2001-4839	19991220
HU 2001004839	A3	20030128		
AU 759892	B2	20030501	AU 2000-24329	19991220
JP 2003517449	T	20030527	JP 2000-591024	19991220
RU 2228333	C2	20040510	RU 2001-120380	19991220
CN 1554651	A	20041215	CN 2004-10047645	19991220
MX 2001PA06590	A	20020311	MX 2001-PA6590	20010626
NO 2001003242	A	20010628	NO 2001-3242	20010628
US 6596758	B1	20030722	US 2001-869518	20010629
IN 2001KN00760	A	20060127	IN 2001-KN760	20010723
ZA 2001006177	A	20021028	ZA 2001-6177	20010726
HK 1047584	A1	20050527	HK 2002-108653	20021129

PRIORITY APPLN. INFO.: FR 1998-16574 A 19981229
WO 1999-EP10114 W 19991220

OTHER SOURCE(S): MARPAT 133:89445
GI



I

AB The title compds. I [X = O, S; A = (CH2)sCO(CH2)t, (CH2)sCR3R4(CH2)t and s = t = 0, or one of s and t is 0 and the other is 1; R1, R2 = H, alkyl, alkenyl, alkynyl, etc.; R = halo, cyano, NO2, etc.] were prepared E.g., (2E,4E)-5-(2-pentyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid was prepared The hypolipidemic and antidiabetic activity of I were investigated.

IT 280585-34-4P 280585-39-9P 280585-41-3P
280585-43-5P 280585-45-7P 280585-47-9P
280585-48-0P 280585-50-4P 280585-51-5P
280585-53-7P 280585-55-9P 280585-57-1P
280585-60-6P 280585-64-0P 280585-66-2P
280585-68-4P 280585-70-8P 280585-72-0P
280585-74-2P 280585-77-5P 280585-81-1P
280585-83-3P 280585-93-5P 280586-01-8P
280586-03-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzopyrans and benzoxepines and their hypolipidemic and antidiabetic activity)

RN 280585-34-4 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-39-9 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2Z,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-41-3 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7,8-dimethoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-43-5 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-45-7 CAPLUS
CN 2,4-Pentadienoic acid, 5-[7-(4-chlorobenzoyl)-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-47-9 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7-chloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-48-0 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7,8-dichloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-50-4 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7-bromo-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-51-5 CAPLUS
CN 2,4-Pentadienoic acid, 5-(8-chloro-7-fluoro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-53-7 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7-fluoro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-55-9 CAPLUS
CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-3,3-dimethyl-7-(trifluoromethyl)-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-57-1 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3-dimethyl-7-phenyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-60-6 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-6-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-64-0 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7-ethyl-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-66-2 CAPLUS
CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-7-(4-methoxyphenyl)-3,3-dimethyl-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-68-4 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3,7,8-tetramethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-70-8 CAPLUS
CN 2,4-Pentadienoic acid, 5-[8-(4-fluorophenyl)-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-72-0 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-8-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-74-2 CAPLUS
CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-3,3-dimethyl-7-(1-methylethyl)-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-77-5 CAPLUS
CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-3,3-dimethyl-7-(trifluoromethoxy)-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-81-1 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-hydroxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-83-3 CAPLUS
CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-3,3-dimethyl-7-[4-(trifluoromethyl)phenyl]-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-93-5 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7-cyclohexyl-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280586-01-8 CAPLUS
CN 2,4-Pentadienoic acid, 5-(7-ethoxy-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280586-03-0 CAPLUS
CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3,7-trimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 09:09:40 ON 16 JUL 2008)

     FILE 'REGISTRY' ENTERED AT 09:10:00 ON 16 JUL 2008
L1             STRUCTURE UPLOADED
L2          26 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 09:10:25 ON 16 JUL 2008
L3           9 S L2 FULL

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    50.01     228.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -7.20      -7.20

STN INTERNATIONAL LOGOFF AT 09:11:42 ON 16 JUL 2008
```